KRTX - UBS Bullish On This Depression Drug Maker Says Alzheimer's Agitation Data Is Attractive Catalyst | Benzinga
UBS initiated coverage on Axsome Therapeutics Inc (NASDAQ:AXSM), a biotech firm focused on developing and marketing therapies for central nervous disorders.
UBS analyst is bullish on Axsom’s depression drug Auvelity’s launch and pipeline opportunities with upcoming late-stage clinical read-outs.
Related Content: Axsome Depression Drug’s Commercial Success, Pipeline Potential Undervalued, Analyst Says.
The analyst anticipates that Auvelity could become a leading brand in depression treatment, generating $1 billion in sales by 2030; UBS’s bottom-up analysis shows that Auvelity can achieve near-term consensus estimates.
UBS initiates coverage with a Buy rating and a price target of $111.
Positive data in Phase 3 trials for Alzheimer’s Agitation and Narcolepsy is expected to boost the performance of Axsome Therapeutics’ stock.
The stock is currently benefiting from increased ...